Researchers in the United Kingdom compared the potential impact on carbon footprint and asthma symptom control of switching maintenance therapy to a dry powder inhaler vs continuing with a metered ...
AstraZeneca will discontinue the production of PULMICORT® (budesonide) 100 and 200 µg/dose HFA pMDI (pressurised metered dose inhaler) due to complex manufacturing issues related to technical aspects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback